Ontunisertib: A New Drug That Tries to Reverse Organ Scarring
What is Ontunisertib?
Ontunisertib (on-TOO-ni-SER-tib) is a brand new medicine being tested by a company called AgomAb Therapeutics (NASDAQ: AGMB). It is a pill you swallow. It is designed to stop and maybe even reverse scarring inside the body.
Scarring happens when the body tries to heal a wound but makes too much tough, stiff tissue. This stiff tissue is called fibrosis (fye-BRO-sis). Over time, fibrosis makes organs — like the lungs, liver, kidneys, and intestines — hard and unable to do their job. This is a big part of why our bodies break down as we get older.
Ontunisertib is being tested first in people with a type of Crohn's disease where the intestines get so scarred they become narrow and blocked.
How does it work?
Think of your body's healing system like a construction crew. When you get a cut, the crew shows up and builds a scar to close the wound. Then the crew is supposed to leave.
But sometimes, the crew never leaves. They keep building and building. Your organs get stiff and stop working.
There is a signal in the body called TGF-beta (T-G-F beta). It is like the foreman who tells the construction crew to keep working.
Ontunisertib blocks that foreman. It tells the crew to stop building. In early tests, this helped reduce scarring and let organs work better.
AgomAb has another version called AGMB-447. It is an inhaled medicine — you breathe it into your lungs. It is being tested for a lung-scarring disease called Idiopathic Pulmonary Fibrosis (IPF).
Who is it for?
Right now, ontunisertib is being tested for:
- People with Fibrostenosing Crohn's Disease — a type of Crohn's where scarring narrows the intestines
AGMB-447 is being tested for:
- People with Idiopathic Pulmonary Fibrosis (IPF) — a disease where the lungs scar up for unknown reasons
But if these drugs work, they could one day help with many other scarring problems — liver scarring (cirrhosis), kidney scarring, heart scarring. Even normal aging involves a slow buildup of scar tissue in all our organs.
Where does it stand?
Ontunisertib (the Crohn's pill)
| Stage | Status |
|---|---|
| Lab tests (cells and animals) | ✅ Done |
| Phase 1 (safety in humans) | ✅ Done |
| Phase 2a (early proof it works) | ✅ Positive results |
| Phase 2b (bigger test) | 🔄 Starting late 2026 |
| Phase 3 (biggest test before approval) | ❌ Not yet |
| FDA approval | ❌ Not yet |
AGMB-447 (the lung inhaler)
| Stage | Status |
|---|---|
| Lab tests | ✅ Done |
| Phase 1 (safety in humans) | ✅ Done |
| Phase 2 | 🔄 Planned |
| FDA Orphan Drug Designation | ✅ Granted (speeds up review) |
Why does this matter?
Most medicines today treat symptoms. A painkiller helps with pain. A steroid brings down inflammation. But they do not fix the underlying problem.
Ontunisertib and AGMB-447 try to fix the underlying problem: the scarring itself. If they work, they could be some of the first medicines that actually reverse organ damage.
For longevity, this is huge. Scarring and stiffening of organs is one of the main reasons we age. If we can slow down or reverse fibrosis, we might be able to keep organs young and healthy for longer.
AgomAb went public on the Nasdaq stock exchange in February 2026 and raised $200 million. Big investors are betting this approach could work.
What we do not know yet
- These drugs are still being tested. They are NOT approved yet. Only a few hundred people have taken them so far.
- The Phase 2a results for ontunisertib were positive, but the study was small. Bigger studies could show different results.
- We do not know the long-term side effects. Blocking TGF-beta might have unexpected effects because this signal also helps with some normal body functions.
- These drugs are tested in sick patients with specific diseases. We have no idea if they would help healthy people age better.
- AgomAb is a young company. Their drugs could fail in later testing. This is common in drug development.
The bottom line
AgomAb is testing medicines that try to reverse organ scarring — a key part of aging. The drugs are in mid-stage human trials. Early results look promising, but they are years away from possible approval. For now, this is exciting science worth watching.
Sources
- AgomAb Therapeutics website — agomab.com
- AgomAb press release: "Design of NOV-ERA Phase 2b Study with Ontunisertib" (June 23, 2026)
- Fierce Biotech: "Agomab's ALK5 inhibitor hits target in phase 2 Crohn's disease trial" (March 10, 2025)
- Seeking Alpha: "AgomAb Therapeutics: High Risk, High Reward Stock (NASDAQ:AGMB)" (June 4, 2026)
- FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis (June 2024)